nodes	percent_of_prediction	percent_of_DWPC	metapath
Bicalutamide—prostate cancer—testicular cancer	0.751	1	CtDrD
Bicalutamide—CYP2C19—Ifosfamide—testicular cancer	0.0269	0.249	CbGbCtD
Bicalutamide—CYP2C9—Ifosfamide—testicular cancer	0.0223	0.207	CbGbCtD
Bicalutamide—CYP3A4—Ifosfamide—testicular cancer	0.013	0.12	CbGbCtD
Bicalutamide—AR—scrotum—testicular cancer	0.0125	0.391	CbGeAlD
Bicalutamide—CYP2C9—Cisplatin—testicular cancer	0.0109	0.101	CbGbCtD
Bicalutamide—CYP2D6—Vinblastine—testicular cancer	0.0108	0.1	CbGbCtD
Bicalutamide—AR—seminiferous tubule of testis—testicular cancer	0.00969	0.304	CbGeAlD
Bicalutamide—CYP3A4—Vinblastine—testicular cancer	0.00689	0.0639	CbGbCtD
Bicalutamide—CYP2D6—Doxorubicin—testicular cancer	0.00666	0.0617	CbGbCtD
Bicalutamide—CYP3A4—Etoposide—testicular cancer	0.0062	0.0575	CbGbCtD
Bicalutamide—AR—semen—testicular cancer	0.00535	0.168	CbGeAlD
Bicalutamide—CYP3A4—Doxorubicin—testicular cancer	0.00423	0.0392	CbGbCtD
Bicalutamide—AR—seminal vesicle—testicular cancer	0.00114	0.0357	CbGeAlD
Bicalutamide—AR—gonad—testicular cancer	0.00082	0.0258	CbGeAlD
Bicalutamide—AR—female gonad—testicular cancer	0.000667	0.021	CbGeAlD
Bicalutamide—AR—testis—testicular cancer	0.000591	0.0186	CbGeAlD
Bicalutamide—AR—lymph node—testicular cancer	0.000429	0.0135	CbGeAlD
Bicalutamide—CYP2D6—female gonad—testicular cancer	0.000359	0.0113	CbGeAlD
Bicalutamide—CYP2D6—testis—testicular cancer	0.000319	0.01	CbGeAlD
Bicalutamide—Bronchitis—Doxorubicin—testicular cancer	7.71e-05	0.000708	CcSEcCtD
Bicalutamide—Rash—Dactinomycin—testicular cancer	7.66e-05	0.000703	CcSEcCtD
Bicalutamide—Decreased appetite—Etoposide—testicular cancer	7.65e-05	0.000702	CcSEcCtD
Bicalutamide—Diarrhoea—Ifosfamide—testicular cancer	7.62e-05	0.000699	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Etoposide—testicular cancer	7.59e-05	0.000697	CcSEcCtD
Bicalutamide—Body temperature increased—Cisplatin—testicular cancer	7.59e-05	0.000696	CcSEcCtD
Bicalutamide—Fatigue—Etoposide—testicular cancer	7.58e-05	0.000696	CcSEcCtD
Bicalutamide—Neuropathy peripheral—Epirubicin—testicular cancer	7.58e-05	0.000695	CcSEcCtD
Bicalutamide—Jaundice—Epirubicin—testicular cancer	7.53e-05	0.000691	CcSEcCtD
Bicalutamide—Pain—Etoposide—testicular cancer	7.52e-05	0.00069	CcSEcCtD
Bicalutamide—Constipation—Etoposide—testicular cancer	7.52e-05	0.00069	CcSEcCtD
Bicalutamide—Conjunctivitis—Epirubicin—testicular cancer	7.51e-05	0.000689	CcSEcCtD
Bicalutamide—Urinary tract infection—Epirubicin—testicular cancer	7.51e-05	0.000689	CcSEcCtD
Bicalutamide—Dysuria—Doxorubicin—testicular cancer	7.5e-05	0.000688	CcSEcCtD
Bicalutamide—Neutropenia—Doxorubicin—testicular cancer	7.5e-05	0.000688	CcSEcCtD
Bicalutamide—Haemoglobin—Methotrexate—testicular cancer	7.45e-05	0.000684	CcSEcCtD
Bicalutamide—Haemorrhage—Methotrexate—testicular cancer	7.42e-05	0.00068	CcSEcCtD
Bicalutamide—Sweating—Epirubicin—testicular cancer	7.41e-05	0.00068	CcSEcCtD
Bicalutamide—Pollakiuria—Doxorubicin—testicular cancer	7.41e-05	0.00068	CcSEcCtD
Bicalutamide—Haematuria—Epirubicin—testicular cancer	7.37e-05	0.000676	CcSEcCtD
Bicalutamide—Dizziness—Ifosfamide—testicular cancer	7.36e-05	0.000676	CcSEcCtD
Bicalutamide—Pharyngitis—Methotrexate—testicular cancer	7.36e-05	0.000675	CcSEcCtD
Bicalutamide—Urinary tract disorder—Methotrexate—testicular cancer	7.32e-05	0.000672	CcSEcCtD
Bicalutamide—Hepatobiliary disease—Epirubicin—testicular cancer	7.31e-05	0.000671	CcSEcCtD
Bicalutamide—Weight increased—Doxorubicin—testicular cancer	7.3e-05	0.00067	CcSEcCtD
Bicalutamide—Epistaxis—Epirubicin—testicular cancer	7.29e-05	0.000669	CcSEcCtD
Bicalutamide—Urethral disorder—Methotrexate—testicular cancer	7.27e-05	0.000667	CcSEcCtD
Bicalutamide—Weight decreased—Doxorubicin—testicular cancer	7.26e-05	0.000666	CcSEcCtD
Bicalutamide—Sinusitis—Epirubicin—testicular cancer	7.25e-05	0.000665	CcSEcCtD
Bicalutamide—Feeling abnormal—Etoposide—testicular cancer	7.25e-05	0.000665	CcSEcCtD
Bicalutamide—Hyperglycaemia—Doxorubicin—testicular cancer	7.24e-05	0.000664	CcSEcCtD
Bicalutamide—Nausea—Dactinomycin—testicular cancer	7.22e-05	0.000662	CcSEcCtD
Bicalutamide—Pneumonia—Doxorubicin—testicular cancer	7.19e-05	0.00066	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Etoposide—testicular cancer	7.19e-05	0.00066	CcSEcCtD
Bicalutamide—Visual impairment—Methotrexate—testicular cancer	7.15e-05	0.000656	CcSEcCtD
Bicalutamide—Vomiting—Ifosfamide—testicular cancer	7.08e-05	0.00065	CcSEcCtD
Bicalutamide—Hypersensitivity—Cisplatin—testicular cancer	7.07e-05	0.000649	CcSEcCtD
Bicalutamide—Bradycardia—Epirubicin—testicular cancer	7.06e-05	0.000648	CcSEcCtD
Bicalutamide—Rash—Ifosfamide—testicular cancer	7.02e-05	0.000644	CcSEcCtD
Bicalutamide—Dermatitis—Ifosfamide—testicular cancer	7.02e-05	0.000644	CcSEcCtD
Bicalutamide—Neuropathy peripheral—Doxorubicin—testicular cancer	7.01e-05	0.000643	CcSEcCtD
Bicalutamide—Urticaria—Etoposide—testicular cancer	6.99e-05	0.000641	CcSEcCtD
Bicalutamide—Haemoglobin—Epirubicin—testicular cancer	6.97e-05	0.00064	CcSEcCtD
Bicalutamide—Jaundice—Doxorubicin—testicular cancer	6.97e-05	0.00064	CcSEcCtD
Bicalutamide—Rhinitis—Epirubicin—testicular cancer	6.96e-05	0.000638	CcSEcCtD
Bicalutamide—Abdominal pain—Etoposide—testicular cancer	6.95e-05	0.000638	CcSEcCtD
Bicalutamide—Body temperature increased—Etoposide—testicular cancer	6.95e-05	0.000638	CcSEcCtD
Bicalutamide—Urinary tract infection—Doxorubicin—testicular cancer	6.95e-05	0.000638	CcSEcCtD
Bicalutamide—Conjunctivitis—Doxorubicin—testicular cancer	6.95e-05	0.000638	CcSEcCtD
Bicalutamide—Haemorrhage—Epirubicin—testicular cancer	6.94e-05	0.000637	CcSEcCtD
Bicalutamide—Asthenia—Cisplatin—testicular cancer	6.89e-05	0.000632	CcSEcCtD
Bicalutamide—Pharyngitis—Epirubicin—testicular cancer	6.89e-05	0.000632	CcSEcCtD
Bicalutamide—Cardiac disorder—Methotrexate—testicular cancer	6.88e-05	0.000631	CcSEcCtD
Bicalutamide—Sweating—Doxorubicin—testicular cancer	6.86e-05	0.000629	CcSEcCtD
Bicalutamide—Urinary tract disorder—Epirubicin—testicular cancer	6.85e-05	0.000629	CcSEcCtD
Bicalutamide—Oedema peripheral—Epirubicin—testicular cancer	6.84e-05	0.000627	CcSEcCtD
Bicalutamide—Haematuria—Doxorubicin—testicular cancer	6.82e-05	0.000626	CcSEcCtD
Bicalutamide—Urethral disorder—Epirubicin—testicular cancer	6.8e-05	0.000624	CcSEcCtD
Bicalutamide—Hepatobiliary disease—Doxorubicin—testicular cancer	6.76e-05	0.000621	CcSEcCtD
Bicalutamide—Epistaxis—Doxorubicin—testicular cancer	6.75e-05	0.000619	CcSEcCtD
Bicalutamide—Angiopathy—Methotrexate—testicular cancer	6.73e-05	0.000617	CcSEcCtD
Bicalutamide—Sinusitis—Doxorubicin—testicular cancer	6.71e-05	0.000616	CcSEcCtD
Bicalutamide—Immune system disorder—Methotrexate—testicular cancer	6.7e-05	0.000615	CcSEcCtD
Bicalutamide—Visual impairment—Epirubicin—testicular cancer	6.69e-05	0.000614	CcSEcCtD
Bicalutamide—Mediastinal disorder—Methotrexate—testicular cancer	6.68e-05	0.000613	CcSEcCtD
Bicalutamide—Chills—Methotrexate—testicular cancer	6.65e-05	0.00061	CcSEcCtD
Bicalutamide—Nausea—Ifosfamide—testicular cancer	6.61e-05	0.000607	CcSEcCtD
Bicalutamide—Diarrhoea—Cisplatin—testicular cancer	6.57e-05	0.000603	CcSEcCtD
Bicalutamide—Alopecia—Methotrexate—testicular cancer	6.55e-05	0.000601	CcSEcCtD
Bicalutamide—Bradycardia—Doxorubicin—testicular cancer	6.54e-05	0.0006	CcSEcCtD
Bicalutamide—Mental disorder—Methotrexate—testicular cancer	6.5e-05	0.000596	CcSEcCtD
Bicalutamide—Hypersensitivity—Etoposide—testicular cancer	6.48e-05	0.000595	CcSEcCtD
Bicalutamide—Malnutrition—Methotrexate—testicular cancer	6.46e-05	0.000592	CcSEcCtD
Bicalutamide—Haemoglobin—Doxorubicin—testicular cancer	6.45e-05	0.000592	CcSEcCtD
Bicalutamide—Cardiac disorder—Epirubicin—testicular cancer	6.44e-05	0.000591	CcSEcCtD
Bicalutamide—Rhinitis—Doxorubicin—testicular cancer	6.44e-05	0.000591	CcSEcCtD
Bicalutamide—Haemorrhage—Doxorubicin—testicular cancer	6.42e-05	0.000589	CcSEcCtD
Bicalutamide—Pharyngitis—Doxorubicin—testicular cancer	6.37e-05	0.000585	CcSEcCtD
Bicalutamide—Urinary tract disorder—Doxorubicin—testicular cancer	6.34e-05	0.000582	CcSEcCtD
Bicalutamide—Oedema peripheral—Doxorubicin—testicular cancer	6.33e-05	0.00058	CcSEcCtD
Bicalutamide—Asthenia—Etoposide—testicular cancer	6.31e-05	0.000579	CcSEcCtD
Bicalutamide—Angiopathy—Epirubicin—testicular cancer	6.3e-05	0.000578	CcSEcCtD
Bicalutamide—Urethral disorder—Doxorubicin—testicular cancer	6.29e-05	0.000578	CcSEcCtD
Bicalutamide—Immune system disorder—Epirubicin—testicular cancer	6.27e-05	0.000575	CcSEcCtD
Bicalutamide—Mediastinal disorder—Epirubicin—testicular cancer	6.25e-05	0.000574	CcSEcCtD
Bicalutamide—Back pain—Methotrexate—testicular cancer	6.24e-05	0.000573	CcSEcCtD
Bicalutamide—Chills—Epirubicin—testicular cancer	6.23e-05	0.000571	CcSEcCtD
Bicalutamide—Pruritus—Etoposide—testicular cancer	6.22e-05	0.000571	CcSEcCtD
Bicalutamide—Arrhythmia—Epirubicin—testicular cancer	6.2e-05	0.000569	CcSEcCtD
Bicalutamide—Visual impairment—Doxorubicin—testicular cancer	6.19e-05	0.000568	CcSEcCtD
Bicalutamide—Alopecia—Epirubicin—testicular cancer	6.13e-05	0.000563	CcSEcCtD
Bicalutamide—Vomiting—Cisplatin—testicular cancer	6.1e-05	0.00056	CcSEcCtD
Bicalutamide—Mental disorder—Epirubicin—testicular cancer	6.08e-05	0.000558	CcSEcCtD
Bicalutamide—Rash—Cisplatin—testicular cancer	6.05e-05	0.000555	CcSEcCtD
Bicalutamide—Dermatitis—Cisplatin—testicular cancer	6.05e-05	0.000555	CcSEcCtD
Bicalutamide—Malnutrition—Epirubicin—testicular cancer	6.04e-05	0.000554	CcSEcCtD
Bicalutamide—Diarrhoea—Etoposide—testicular cancer	6.02e-05	0.000552	CcSEcCtD
Bicalutamide—Anaemia—Methotrexate—testicular cancer	5.97e-05	0.000547	CcSEcCtD
Bicalutamide—Cardiac disorder—Doxorubicin—testicular cancer	5.96e-05	0.000547	CcSEcCtD
Bicalutamide—Flatulence—Epirubicin—testicular cancer	5.95e-05	0.000546	CcSEcCtD
Bicalutamide—Tension—Epirubicin—testicular cancer	5.93e-05	0.000544	CcSEcCtD
Bicalutamide—Nervousness—Epirubicin—testicular cancer	5.87e-05	0.000538	CcSEcCtD
Bicalutamide—Back pain—Epirubicin—testicular cancer	5.84e-05	0.000536	CcSEcCtD
Bicalutamide—Angiopathy—Doxorubicin—testicular cancer	5.83e-05	0.000535	CcSEcCtD
Bicalutamide—Dizziness—Etoposide—testicular cancer	5.82e-05	0.000534	CcSEcCtD
Bicalutamide—Muscle spasms—Epirubicin—testicular cancer	5.81e-05	0.000533	CcSEcCtD
Bicalutamide—Immune system disorder—Doxorubicin—testicular cancer	5.8e-05	0.000532	CcSEcCtD
Bicalutamide—Mediastinal disorder—Doxorubicin—testicular cancer	5.79e-05	0.000531	CcSEcCtD
Bicalutamide—Chills—Doxorubicin—testicular cancer	5.76e-05	0.000529	CcSEcCtD
Bicalutamide—Arrhythmia—Doxorubicin—testicular cancer	5.74e-05	0.000526	CcSEcCtD
Bicalutamide—Nausea—Cisplatin—testicular cancer	5.7e-05	0.000523	CcSEcCtD
Bicalutamide—Alopecia—Doxorubicin—testicular cancer	5.67e-05	0.000521	CcSEcCtD
Bicalutamide—Cough—Methotrexate—testicular cancer	5.63e-05	0.000517	CcSEcCtD
Bicalutamide—Mental disorder—Doxorubicin—testicular cancer	5.63e-05	0.000516	CcSEcCtD
Bicalutamide—Vomiting—Etoposide—testicular cancer	5.59e-05	0.000513	CcSEcCtD
Bicalutamide—Malnutrition—Doxorubicin—testicular cancer	5.59e-05	0.000513	CcSEcCtD
Bicalutamide—Anaemia—Epirubicin—testicular cancer	5.58e-05	0.000512	CcSEcCtD
Bicalutamide—Rash—Etoposide—testicular cancer	5.55e-05	0.000509	CcSEcCtD
Bicalutamide—Dermatitis—Etoposide—testicular cancer	5.54e-05	0.000508	CcSEcCtD
Bicalutamide—Headache—Etoposide—testicular cancer	5.51e-05	0.000506	CcSEcCtD
Bicalutamide—Flatulence—Doxorubicin—testicular cancer	5.51e-05	0.000505	CcSEcCtD
Bicalutamide—Myalgia—Methotrexate—testicular cancer	5.5e-05	0.000504	CcSEcCtD
Bicalutamide—Chest pain—Methotrexate—testicular cancer	5.5e-05	0.000504	CcSEcCtD
Bicalutamide—Tension—Doxorubicin—testicular cancer	5.49e-05	0.000503	CcSEcCtD
Bicalutamide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	5.46e-05	0.000501	CcSEcCtD
Bicalutamide—Nervousness—Doxorubicin—testicular cancer	5.43e-05	0.000498	CcSEcCtD
Bicalutamide—Syncope—Epirubicin—testicular cancer	5.42e-05	0.000497	CcSEcCtD
Bicalutamide—Back pain—Doxorubicin—testicular cancer	5.41e-05	0.000496	CcSEcCtD
Bicalutamide—Muscle spasms—Doxorubicin—testicular cancer	5.37e-05	0.000493	CcSEcCtD
Bicalutamide—Confusional state—Methotrexate—testicular cancer	5.31e-05	0.000487	CcSEcCtD
Bicalutamide—Loss of consciousness—Epirubicin—testicular cancer	5.31e-05	0.000487	CcSEcCtD
Bicalutamide—Cough—Epirubicin—testicular cancer	5.27e-05	0.000484	CcSEcCtD
Bicalutamide—Infection—Methotrexate—testicular cancer	5.23e-05	0.00048	CcSEcCtD
Bicalutamide—Nausea—Etoposide—testicular cancer	5.22e-05	0.000479	CcSEcCtD
Bicalutamide—Hypertension—Epirubicin—testicular cancer	5.22e-05	0.000479	CcSEcCtD
Bicalutamide—Nervous system disorder—Methotrexate—testicular cancer	5.17e-05	0.000474	CcSEcCtD
Bicalutamide—Anaemia—Doxorubicin—testicular cancer	5.17e-05	0.000474	CcSEcCtD
Bicalutamide—Thrombocytopenia—Methotrexate—testicular cancer	5.16e-05	0.000473	CcSEcCtD
Bicalutamide—Chest pain—Epirubicin—testicular cancer	5.14e-05	0.000472	CcSEcCtD
Bicalutamide—Myalgia—Epirubicin—testicular cancer	5.14e-05	0.000472	CcSEcCtD
Bicalutamide—Anxiety—Epirubicin—testicular cancer	5.13e-05	0.00047	CcSEcCtD
Bicalutamide—Skin disorder—Methotrexate—testicular cancer	5.12e-05	0.00047	CcSEcCtD
Bicalutamide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	5.11e-05	0.000469	CcSEcCtD
Bicalutamide—Hyperhidrosis—Methotrexate—testicular cancer	5.09e-05	0.000467	CcSEcCtD
Bicalutamide—Dry mouth—Epirubicin—testicular cancer	5.03e-05	0.000462	CcSEcCtD
Bicalutamide—Anorexia—Methotrexate—testicular cancer	5.02e-05	0.000461	CcSEcCtD
Bicalutamide—Syncope—Doxorubicin—testicular cancer	5.01e-05	0.00046	CcSEcCtD
Bicalutamide—Confusional state—Epirubicin—testicular cancer	4.97e-05	0.000456	CcSEcCtD
Bicalutamide—Oedema—Epirubicin—testicular cancer	4.93e-05	0.000452	CcSEcCtD
Bicalutamide—Loss of consciousness—Doxorubicin—testicular cancer	4.91e-05	0.000451	CcSEcCtD
Bicalutamide—Infection—Epirubicin—testicular cancer	4.9e-05	0.000449	CcSEcCtD
Bicalutamide—Cough—Doxorubicin—testicular cancer	4.88e-05	0.000448	CcSEcCtD
Bicalutamide—Shock—Epirubicin—testicular cancer	4.85e-05	0.000445	CcSEcCtD
Bicalutamide—Nervous system disorder—Epirubicin—testicular cancer	4.83e-05	0.000444	CcSEcCtD
Bicalutamide—Thrombocytopenia—Epirubicin—testicular cancer	4.83e-05	0.000443	CcSEcCtD
Bicalutamide—Hypertension—Doxorubicin—testicular cancer	4.83e-05	0.000443	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Methotrexate—testicular cancer	4.8e-05	0.00044	CcSEcCtD
Bicalutamide—Skin disorder—Epirubicin—testicular cancer	4.79e-05	0.000439	CcSEcCtD
Bicalutamide—Hyperhidrosis—Epirubicin—testicular cancer	4.77e-05	0.000437	CcSEcCtD
Bicalutamide—Insomnia—Methotrexate—testicular cancer	4.76e-05	0.000437	CcSEcCtD
Bicalutamide—Chest pain—Doxorubicin—testicular cancer	4.76e-05	0.000437	CcSEcCtD
Bicalutamide—Myalgia—Doxorubicin—testicular cancer	4.76e-05	0.000437	CcSEcCtD
Bicalutamide—Anxiety—Doxorubicin—testicular cancer	4.74e-05	0.000435	CcSEcCtD
Bicalutamide—Paraesthesia—Methotrexate—testicular cancer	4.73e-05	0.000434	CcSEcCtD
Bicalutamide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	4.73e-05	0.000434	CcSEcCtD
Bicalutamide—Anorexia—Epirubicin—testicular cancer	4.7e-05	0.000431	CcSEcCtD
Bicalutamide—Dyspnoea—Methotrexate—testicular cancer	4.7e-05	0.000431	CcSEcCtD
Bicalutamide—Somnolence—Methotrexate—testicular cancer	4.68e-05	0.00043	CcSEcCtD
Bicalutamide—Dry mouth—Doxorubicin—testicular cancer	4.65e-05	0.000427	CcSEcCtD
Bicalutamide—Dyspepsia—Methotrexate—testicular cancer	4.64e-05	0.000425	CcSEcCtD
Bicalutamide—Confusional state—Doxorubicin—testicular cancer	4.6e-05	0.000422	CcSEcCtD
Bicalutamide—Decreased appetite—Methotrexate—testicular cancer	4.58e-05	0.00042	CcSEcCtD
Bicalutamide—Oedema—Doxorubicin—testicular cancer	4.56e-05	0.000419	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Methotrexate—testicular cancer	4.55e-05	0.000417	CcSEcCtD
Bicalutamide—Fatigue—Methotrexate—testicular cancer	4.54e-05	0.000417	CcSEcCtD
Bicalutamide—Infection—Doxorubicin—testicular cancer	4.53e-05	0.000416	CcSEcCtD
Bicalutamide—Pain—Methotrexate—testicular cancer	4.51e-05	0.000413	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Epirubicin—testicular cancer	4.49e-05	0.000412	CcSEcCtD
Bicalutamide—Shock—Doxorubicin—testicular cancer	4.49e-05	0.000412	CcSEcCtD
Bicalutamide—Nervous system disorder—Doxorubicin—testicular cancer	4.47e-05	0.00041	CcSEcCtD
Bicalutamide—Thrombocytopenia—Doxorubicin—testicular cancer	4.47e-05	0.00041	CcSEcCtD
Bicalutamide—Insomnia—Epirubicin—testicular cancer	4.46e-05	0.000409	CcSEcCtD
Bicalutamide—Skin disorder—Doxorubicin—testicular cancer	4.43e-05	0.000407	CcSEcCtD
Bicalutamide—Paraesthesia—Epirubicin—testicular cancer	4.43e-05	0.000406	CcSEcCtD
Bicalutamide—Hyperhidrosis—Doxorubicin—testicular cancer	4.41e-05	0.000405	CcSEcCtD
Bicalutamide—Dyspnoea—Epirubicin—testicular cancer	4.4e-05	0.000403	CcSEcCtD
Bicalutamide—Somnolence—Epirubicin—testicular cancer	4.38e-05	0.000402	CcSEcCtD
Bicalutamide—Anorexia—Doxorubicin—testicular cancer	4.35e-05	0.000399	CcSEcCtD
Bicalutamide—Feeling abnormal—Methotrexate—testicular cancer	4.34e-05	0.000398	CcSEcCtD
Bicalutamide—Dyspepsia—Epirubicin—testicular cancer	4.34e-05	0.000398	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Methotrexate—testicular cancer	4.31e-05	0.000395	CcSEcCtD
Bicalutamide—Decreased appetite—Epirubicin—testicular cancer	4.29e-05	0.000393	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Epirubicin—testicular cancer	4.26e-05	0.000391	CcSEcCtD
Bicalutamide—Fatigue—Epirubicin—testicular cancer	4.25e-05	0.00039	CcSEcCtD
Bicalutamide—Pain—Epirubicin—testicular cancer	4.22e-05	0.000387	CcSEcCtD
Bicalutamide—Constipation—Epirubicin—testicular cancer	4.22e-05	0.000387	CcSEcCtD
Bicalutamide—Urticaria—Methotrexate—testicular cancer	4.19e-05	0.000384	CcSEcCtD
Bicalutamide—Abdominal pain—Methotrexate—testicular cancer	4.16e-05	0.000382	CcSEcCtD
Bicalutamide—Body temperature increased—Methotrexate—testicular cancer	4.16e-05	0.000382	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Doxorubicin—testicular cancer	4.16e-05	0.000381	CcSEcCtD
Bicalutamide—Insomnia—Doxorubicin—testicular cancer	4.13e-05	0.000379	CcSEcCtD
Bicalutamide—Paraesthesia—Doxorubicin—testicular cancer	4.1e-05	0.000376	CcSEcCtD
Bicalutamide—Dyspnoea—Doxorubicin—testicular cancer	4.07e-05	0.000373	CcSEcCtD
Bicalutamide—Feeling abnormal—Epirubicin—testicular cancer	4.06e-05	0.000373	CcSEcCtD
Bicalutamide—Somnolence—Doxorubicin—testicular cancer	4.06e-05	0.000372	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Epirubicin—testicular cancer	4.03e-05	0.00037	CcSEcCtD
Bicalutamide—Dyspepsia—Doxorubicin—testicular cancer	4.02e-05	0.000368	CcSEcCtD
Bicalutamide—Decreased appetite—Doxorubicin—testicular cancer	3.97e-05	0.000364	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Doxorubicin—testicular cancer	3.94e-05	0.000361	CcSEcCtD
Bicalutamide—Fatigue—Doxorubicin—testicular cancer	3.93e-05	0.000361	CcSEcCtD
Bicalutamide—Urticaria—Epirubicin—testicular cancer	3.92e-05	0.000359	CcSEcCtD
Bicalutamide—Pain—Doxorubicin—testicular cancer	3.9e-05	0.000358	CcSEcCtD
Bicalutamide—Constipation—Doxorubicin—testicular cancer	3.9e-05	0.000358	CcSEcCtD
Bicalutamide—Abdominal pain—Epirubicin—testicular cancer	3.9e-05	0.000358	CcSEcCtD
Bicalutamide—Body temperature increased—Epirubicin—testicular cancer	3.9e-05	0.000358	CcSEcCtD
Bicalutamide—Hypersensitivity—Methotrexate—testicular cancer	3.88e-05	0.000356	CcSEcCtD
Bicalutamide—Asthenia—Methotrexate—testicular cancer	3.78e-05	0.000347	CcSEcCtD
Bicalutamide—Feeling abnormal—Doxorubicin—testicular cancer	3.76e-05	0.000345	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Doxorubicin—testicular cancer	3.73e-05	0.000342	CcSEcCtD
Bicalutamide—Pruritus—Methotrexate—testicular cancer	3.73e-05	0.000342	CcSEcCtD
Bicalutamide—Hypersensitivity—Epirubicin—testicular cancer	3.63e-05	0.000333	CcSEcCtD
Bicalutamide—Urticaria—Doxorubicin—testicular cancer	3.62e-05	0.000333	CcSEcCtD
Bicalutamide—Body temperature increased—Doxorubicin—testicular cancer	3.61e-05	0.000331	CcSEcCtD
Bicalutamide—Abdominal pain—Doxorubicin—testicular cancer	3.61e-05	0.000331	CcSEcCtD
Bicalutamide—Diarrhoea—Methotrexate—testicular cancer	3.6e-05	0.000331	CcSEcCtD
Bicalutamide—Asthenia—Epirubicin—testicular cancer	3.54e-05	0.000325	CcSEcCtD
Bicalutamide—Pruritus—Epirubicin—testicular cancer	3.49e-05	0.00032	CcSEcCtD
Bicalutamide—Dizziness—Methotrexate—testicular cancer	3.48e-05	0.00032	CcSEcCtD
Bicalutamide—Diarrhoea—Epirubicin—testicular cancer	3.37e-05	0.00031	CcSEcCtD
Bicalutamide—Hypersensitivity—Doxorubicin—testicular cancer	3.36e-05	0.000308	CcSEcCtD
Bicalutamide—Vomiting—Methotrexate—testicular cancer	3.35e-05	0.000307	CcSEcCtD
Bicalutamide—Rash—Methotrexate—testicular cancer	3.32e-05	0.000305	CcSEcCtD
Bicalutamide—Dermatitis—Methotrexate—testicular cancer	3.32e-05	0.000304	CcSEcCtD
Bicalutamide—Headache—Methotrexate—testicular cancer	3.3e-05	0.000303	CcSEcCtD
Bicalutamide—Asthenia—Doxorubicin—testicular cancer	3.27e-05	0.0003	CcSEcCtD
Bicalutamide—Dizziness—Epirubicin—testicular cancer	3.26e-05	0.000299	CcSEcCtD
Bicalutamide—Pruritus—Doxorubicin—testicular cancer	3.23e-05	0.000296	CcSEcCtD
Bicalutamide—Vomiting—Epirubicin—testicular cancer	3.13e-05	0.000288	CcSEcCtD
Bicalutamide—Nausea—Methotrexate—testicular cancer	3.13e-05	0.000287	CcSEcCtD
Bicalutamide—Diarrhoea—Doxorubicin—testicular cancer	3.12e-05	0.000286	CcSEcCtD
Bicalutamide—Rash—Epirubicin—testicular cancer	3.11e-05	0.000285	CcSEcCtD
Bicalutamide—Dermatitis—Epirubicin—testicular cancer	3.11e-05	0.000285	CcSEcCtD
Bicalutamide—Headache—Epirubicin—testicular cancer	3.09e-05	0.000283	CcSEcCtD
Bicalutamide—Dizziness—Doxorubicin—testicular cancer	3.02e-05	0.000277	CcSEcCtD
Bicalutamide—Nausea—Epirubicin—testicular cancer	2.93e-05	0.000269	CcSEcCtD
Bicalutamide—Vomiting—Doxorubicin—testicular cancer	2.9e-05	0.000266	CcSEcCtD
Bicalutamide—Rash—Doxorubicin—testicular cancer	2.88e-05	0.000264	CcSEcCtD
Bicalutamide—Dermatitis—Doxorubicin—testicular cancer	2.87e-05	0.000264	CcSEcCtD
Bicalutamide—Headache—Doxorubicin—testicular cancer	2.86e-05	0.000262	CcSEcCtD
Bicalutamide—Nausea—Doxorubicin—testicular cancer	2.71e-05	0.000249	CcSEcCtD
